Michael Schmidt
Stock Analyst at Guggenheim
(4.95)
# 25
Out of 5,129 analysts
116
Total ratings
73.63%
Success rate
53.73%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael Schmidt
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TNGX Tango Therapeutics | Maintains: Buy | $12 → $18 | $12.61 | +42.74% | 2 | Feb 6, 2026 | |
| NBTX Nanobiotix | Maintains: Buy | $8 → $26 | $24.12 | +7.79% | 3 | Feb 6, 2026 | |
| RVMD Revolution Medicines | Maintains: Buy | $92 → $160 | $97.99 | +63.28% | 5 | Jan 20, 2026 | |
| CTMX CytomX Therapeutics | Initiates: Buy | $10 | $5.56 | +79.86% | 1 | Jan 20, 2026 | |
| GLUE Monte Rosa Therapeutics | Maintains: Buy | $16 → $34 | $18.96 | +79.32% | 2 | Jan 8, 2026 | |
| IMNM Immunome | Maintains: Buy | $25 → $35 | $23.41 | +49.51% | 4 | Dec 16, 2025 | |
| FHTX Foghorn Therapeutics | Initiates: Buy | $12 | $5.43 | +120.99% | 1 | Nov 7, 2025 | |
| INCY Incyte | Upgrades: Buy | $125 | $98.84 | +26.47% | 7 | Nov 3, 2025 | |
| GMAB Genmab | Upgrades: Buy | $43 | $30.06 | +43.05% | 3 | Sep 23, 2025 | |
| ADCT ADC Therapeutics | Reiterates: Buy | $10 | $3.92 | +155.10% | 6 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $18 | $10.20 | +76.47% | 6 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $12 | $6.44 | +86.34% | 5 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $350 → $365 | $351.27 | +3.91% | 4 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $15 | $13.09 | +14.59% | 6 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $17 | $37.20 | -54.30% | 1 | Jul 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $45 | $21.62 | +108.14% | 2 | Jun 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $15 | $21.14 | -29.04% | 1 | May 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $52 | $82.27 | -36.79% | 1 | May 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $10 | $9.15 | +9.29% | 1 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $32 | $21.71 | +47.40% | 3 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $14 | $6.34 | +120.82% | 3 | Mar 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $18.54 | - | 1 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $42 | $42.94 | -2.19% | 10 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | n/a | $1.79 | - | 1 | Jan 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $20 | $6.48 | +208.64% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $8 | $2.43 | +229.22% | 3 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $32.97 | - | 3 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $112 | $6.81 | +1,544.64% | 4 | Sep 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $5.02 | - | 2 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $5.05 | - | 2 | Mar 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.65 | - | 1 | Jan 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $34 | $12.22 | +178.23% | 4 | Nov 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $11.56 | +116.26% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $26 | $2.19 | +1,087.21% | 1 | May 18, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.65 | - | 2 | Apr 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $80 | $27.71 | +188.70% | 5 | Feb 15, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $11.10 | - | 6 | Jan 17, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $4 → $5.5 | $4.16 | +32.21% | 2 | Nov 7, 2017 |
Tango Therapeutics
Feb 6, 2026
Maintains: Buy
Price Target: $12 → $18
Current: $12.61
Upside: +42.74%
Nanobiotix
Feb 6, 2026
Maintains: Buy
Price Target: $8 → $26
Current: $24.12
Upside: +7.79%
Revolution Medicines
Jan 20, 2026
Maintains: Buy
Price Target: $92 → $160
Current: $97.99
Upside: +63.28%
CytomX Therapeutics
Jan 20, 2026
Initiates: Buy
Price Target: $10
Current: $5.56
Upside: +79.86%
Monte Rosa Therapeutics
Jan 8, 2026
Maintains: Buy
Price Target: $16 → $34
Current: $18.96
Upside: +79.32%
Immunome
Dec 16, 2025
Maintains: Buy
Price Target: $25 → $35
Current: $23.41
Upside: +49.51%
Foghorn Therapeutics
Nov 7, 2025
Initiates: Buy
Price Target: $12
Current: $5.43
Upside: +120.99%
Incyte
Nov 3, 2025
Upgrades: Buy
Price Target: $125
Current: $98.84
Upside: +26.47%
Genmab
Sep 23, 2025
Upgrades: Buy
Price Target: $43
Current: $30.06
Upside: +43.05%
ADC Therapeutics
Aug 13, 2025
Reiterates: Buy
Price Target: $10
Current: $3.92
Upside: +155.10%
Aug 13, 2025
Reiterates: Buy
Price Target: $18
Current: $10.20
Upside: +76.47%
Aug 12, 2025
Maintains: Buy
Price Target: $10 → $12
Current: $6.44
Upside: +86.34%
Aug 7, 2025
Maintains: Buy
Price Target: $350 → $365
Current: $351.27
Upside: +3.91%
Aug 7, 2025
Maintains: Buy
Price Target: $16 → $15
Current: $13.09
Upside: +14.59%
Jul 8, 2025
Reiterates: Buy
Price Target: $17
Current: $37.20
Upside: -54.30%
Jun 24, 2025
Reiterates: Buy
Price Target: $45
Current: $21.62
Upside: +108.14%
May 23, 2025
Maintains: Buy
Price Target: $40 → $15
Current: $21.14
Upside: -29.04%
May 12, 2025
Reiterates: Buy
Price Target: $52
Current: $82.27
Upside: -36.79%
May 7, 2025
Maintains: Buy
Price Target: $30 → $10
Current: $9.15
Upside: +9.29%
May 6, 2025
Reiterates: Buy
Price Target: $32
Current: $21.71
Upside: +47.40%
Mar 24, 2025
Maintains: Buy
Price Target: $13 → $14
Current: $6.34
Upside: +120.82%
Mar 12, 2025
Reiterates: Neutral
Price Target: n/a
Current: $18.54
Upside: -
Feb 12, 2025
Reiterates: Buy
Price Target: $42
Current: $42.94
Upside: -2.19%
Jan 22, 2025
Reiterates: Buy
Price Target: n/a
Current: $1.79
Upside: -
Dec 6, 2024
Reiterates: Buy
Price Target: $20
Current: $6.48
Upside: +208.64%
Nov 15, 2024
Maintains: Buy
Price Target: $12 → $8
Current: $2.43
Upside: +229.22%
Oct 7, 2024
Downgrades: Neutral
Price Target: n/a
Current: $32.97
Upside: -
Sep 30, 2024
Upgrades: Buy
Price Target: $112
Current: $6.81
Upside: +1,544.64%
May 15, 2024
Downgrades: Neutral
Price Target: n/a
Current: $5.02
Upside: -
Mar 14, 2024
Downgrades: Neutral
Price Target: n/a
Current: $5.05
Upside: -
Jan 5, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.65
Upside: -
Nov 8, 2023
Maintains: Buy
Price Target: $40 → $34
Current: $12.22
Upside: +178.23%
Aug 10, 2021
Initiates: Buy
Price Target: $25
Current: $11.56
Upside: +116.26%
May 18, 2021
Initiates: Buy
Price Target: $26
Current: $2.19
Upside: +1,087.21%
Apr 28, 2021
Downgrades: Neutral
Price Target: n/a
Current: $3.65
Upside: -
Feb 15, 2019
Upgrades: Outperform
Price Target: $80
Current: $27.71
Upside: +188.70%
Jan 17, 2019
Initiates: Outperform
Price Target: n/a
Current: $11.10
Upside: -
Nov 7, 2017
Maintains: Market Perform
Price Target: $4 → $5.5
Current: $4.16
Upside: +32.21%